Diversified Trust Co Buys 8,243 Shares of Ralliant Corporation $RAL

Diversified Trust Co raised its stake in shares of Ralliant Corporation (NYSE:RAL) by 93.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,026 shares of the company’s stock after buying an additional 8,243 shares during the quarter. Diversified Trust Co’s holdings in Ralliant were worth $708,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in RAL. Cetera Investment Advisers bought a new position in shares of Ralliant during the second quarter valued at $700,000. Russell Investments Group Ltd. bought a new position in Ralliant in the 2nd quarter worth about $1,465,000. EverSource Wealth Advisors LLC purchased a new stake in Ralliant during the 2nd quarter valued at about $39,000. First Trust Advisors LP purchased a new stake in Ralliant during the 2nd quarter valued at about $2,013,000. Finally, Federated Hermes Inc. bought a new stake in Ralliant during the 2nd quarter valued at about $326,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Barclays raised their price target on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada boosted their price objective on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Evercore began coverage on Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective on the stock. Finally, TD Cowen increased their target price on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 20th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Stock Up 4.1%

Shares of Ralliant stock opened at $72.09 on Thursday. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $72.97. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The company’s 50 day moving average is $57.06 and its 200 day moving average is $50.94. The company has a market cap of $8.07 billion and a price-to-earnings ratio of -6.59.

Ralliant (NYSE:RAL) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Research analysts anticipate that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.